ABSTRACT
We report the case of a patient who exhibited severe acute hepatitis with symptomatic cholestasis for more than 3 months and bile duct injury following the prescription of atorvastatin. After withdrawal the drug, the patient's wellbeing slowly improves and biological features normalize in 4 months. Therapy aimed at treating severe liver steatosis and hypercholesterolemia. Atorvastatin is a highly effective 3-hydroxy-3 methylglutamyl- coenzyme A reductase (statin) used to lower low-density lipoprotein. Reported frequent adverse events of the medication include nausea, depression, myalgia, abdominal pain and abnormal liver function tests. Although abnormal liver function tests is not an uncommon side effect of the medication, more serious liver injury is rare. In a recent literature review, about ten cases of serious hepatotoxicity have been documented. In the typical presentation, the duration of exposure prior to hepatic toxicity is variable. Liver injury is generally of the mixed type. A prolonged cholestasis for more than 3 months has been seldom reported. Morphological changes includes canalicular cholestasis, feathery degeneration but no cholangiolitis nor cholangitis under the form of cytological and inflammatory changes at the level of interlobular bile ducts. This case report provides further evidence that among statins, atorvastatin may be implicated in drug-induced liver injury and indicates for the first time that such liver injury may be followed by prolonged cholestasis and interlobular bile duct injury. Atorvastatin has thus to be added to the list of medication potentially responsible for bile duct injury.
Subject(s)
Anticholesteremic Agents/adverse effects , Bile Ducts/drug effects , Chemical and Drug Induced Liver Injury/etiology , Cholestasis/chemically induced , Heptanoic Acids/adverse effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Pyrroles/adverse effects , Acute Disease , Atorvastatin , Humans , Male , Middle AgedABSTRACT
Propylthiouracyl (PTU)-related liver toxicity is likely to occur in about 1% of treated patients. In case of acute or subacute hepatitis, liver failure may occur in about one third. We report two further cases of PTU-induced subacute hepatitis, in whom the delay between occurrence of liver damage after the initiation of treatment, the underestimation of its severity and the delayed withdrawal of the drug were all likely responsible for liver failure. The high incidence of liver toxicity related to PTU, its potential severity and delayed occurrence after initiation of treatment are in favor of monthly alanine aminotransferase monitoring, at least during the first six months of therapy.
Subject(s)
Alanine Transaminase/metabolism , Antithyroid Agents/adverse effects , Chemical and Drug Induced Liver Injury/etiology , Liver Failure/etiology , Propylthiouracil/adverse effects , Adult , Female , Humans , Liver/drug effectsABSTRACT
UNLABELLED: Hypervitaminosis A-related liver toxicity may be severe and may even lead to cirrhosis. In the normal liver, vitamin A is stored in hepatic stellate cells (HSC), which are prone to becoming activated and acquiring a myofibroblast-like phenotype, producing large amounts of extracellular matrix. AIMS: In order to assess the relationship between vitamin A intake, HSC activation and fibrosis, we studied nine liver biopsies from patients belonging to a well-characterized series of 41 patients with vitamin A hepatotoxicity. METHODS: Fibrosis was underlined by Sirius-red staining, whereas activated HSC were immunohistochemically identified using an antibody against alpha smooth muscle actin. The volume density (Vv) of sinusoidal and total fibrosis and of sinusoidal and total activated HSC was quantified by the point-counting method. RESULTS: Morphology ranged from HSC hypertrophy and hyperplasia as the sole features to severe architectural distortion. There was a significant positive correlation between Vv of perisinusoidal fibrosis and the daily consumption of vitamin A (P=0.004). CONCLUSION: The close correlation between the severity of perisinusoidal fibrosis and the daily dose of the retinol intake suggests the existence of a dose-effect relationship.
Subject(s)
Hypervitaminosis A/chemically induced , Kupffer Cells/drug effects , Liver Cirrhosis/chemically induced , Vitamin A/adverse effects , Actins/metabolism , Adult , Aged , Biomarkers/metabolism , Cell Enlargement/drug effects , Female , Humans , Hyperplasia/chemically induced , Hyperplasia/pathology , Hypervitaminosis A/pathology , Immunohistochemistry , Kupffer Cells/metabolism , Kupffer Cells/pathology , Liver/drug effects , Liver/metabolism , Liver/pathology , Liver Cirrhosis/pathology , Male , Middle AgedABSTRACT
Elevation of serum alpha-fetoprotein (AFP) in the absence of any liver disease or malignancy, likely of genetic origin, is an uncommon observation which may be the source of diagnostic difficulties in routine clinical practice, especially in cases without available familial data. Animal studies suggest that the anomaly may be related to a mutation located in a regulatory gene different from that mapped for AFP. The transmission pattern of the defect is unknown with a strong suggestion for an autosomal dominant inheritance. We report the cases of two patients in whom a stable elevation of unknown origin of the tumoral marker for up to 10 years, has been observed in the absence of any detectable liver and/or malignancy and in whom the lack of familial data was the source of diagnostic difficulties.
Subject(s)
Biomarkers, Tumor/blood , alpha-Fetoproteins/analysis , Aged , Female , Follow-Up Studies , Humans , Male , Time FactorsSubject(s)
Aneurysm/diagnosis , Portal Vein , Angiography , Female , Humans , Middle Aged , Tomography, X-Ray ComputedABSTRACT
Various drugs of toxins have been implicated in the development of a particular form of liver damage predominantly involving the bile ducts. Such liver toxicity is often associated with a clinical picture of prolonged cholestasis and may even evolve in rare instances, into the full picture of the vanishing bile duct syndrome, eventually complicated with biliary cirrhosis. Drug and toxins potentially responsible for bile duct injury are reviewed as well as the characteristics of its clinical presentation. The pathophysiologic aspects of the syndrome are also reviewed including recent data, which are strongly in favor of the role of a genetic predisposition.
Subject(s)
Bile Duct Diseases/chemically induced , Bile Duct Diseases/diagnosis , Bile Duct Diseases/etiology , Bile Duct Diseases/physiopathology , Chemical and Drug Induced Liver Injury , Cholestasis/chemically induced , Drug-Related Side Effects and Adverse Reactions/diagnosis , Drug-Related Side Effects and Adverse Reactions/physiopathology , Genetic Predisposition to Disease , Humans , Syndrome , Toxins, BiologicalSubject(s)
Anti-Inflammatory Agents, Non-Steroidal/poisoning , Chemical and Drug Induced Liver Injury/etiology , Ibuprofen/poisoning , Liver Transplantation , Chemical and Drug Induced Liver Injury/pathology , Chemical and Drug Induced Liver Injury/surgery , Drug Overdose , Female , Humans , Liver/drug effects , Liver/pathology , Middle AgedSubject(s)
Liver Failure/surgery , Liver Transplantation/statistics & numerical data , Acute Disease , Adolescent , Adult , Aged , Disease-Free Survival , Female , Graft Rejection/epidemiology , Humans , Liver Failure/etiology , Liver Transplantation/mortality , Liver Transplantation/physiology , Male , Middle Aged , Postoperative Complications/classification , Postoperative Complications/epidemiology , Retrospective Studies , Survival Rate , Time FactorsABSTRACT
BACKGROUND & AIMS: Drug-induced immunoallergic hepatitis typically affects a minority of patients exposed to a particular drug. Its rarity is believed to be due to metabolic or immunologic idiosyncrasy. The presence of an immunologic idiosyncrasy might imply an HLA association. Previous studies reporting an HLA association of drug-induced hepatitis included only small numbers of patients and used serological HLA typing. METHODS: We studied 35 patients with biopsy-documented amoxicillin-clavulanate-induced hepatitis. HLA-A and -B were typed using alloantisera and compared with those of 300 controls (volunteer bone marrow donors). HLA-DRB and -DWB were typed by polymerase chain reaction-line probe assay, with 60 volunteer bone marrow donors serving as controls. RESULTS: The study group was characterized by a higher frequency of DRB1*1501-DRB5*0101-DQB1*0602 haplotype (57.1% vs. 11.7% in controls, P < 0.000005; after correction for the large number of comparisons, P < 0.0002). Patients with DRB1*1501-DRB5*0101-DQB1*0602 haplotype were more likely than patients without it to have a cholestatic (70% vs. 60%) or mixed (30% vs. 13%) than a hepatocellular pattern of hepatitis (0% vs. 27%) (P < 0.05). CONCLUSIONS: Amoxicillin-clavulanate-induced hepatitis is associated with the DRB1*1501-DRB5*0101-DQB1*0602 haplotype. The data support the view that an immunologic idiosyncrasy, mediated through HLA class II antigens, plays a role in the pathogenesis of drug-induced immunoallergic hepatitis. HLA association has a limited impact on the expression of hepatitis.
Subject(s)
Amoxicillin/adverse effects , Chemical and Drug Induced Liver Injury/immunology , Clavulanic Acid/adverse effects , Histocompatibility Antigens Class II/analysis , Adult , Aged , Aged, 80 and over , Female , HLA-DQ Antigens/genetics , HLA-DQ beta-Chains , HLA-DR Antigens/genetics , HLA-DRB1 Chains , HLA-DRB5 Chains , Haplotypes , Humans , Male , Middle AgedABSTRACT
BACKGROUND AND AIM: Serum alanine aminotransferase (ALT) level is the most common screening test as part of a routine evaluation of liver damage. In order to determine the factors influencing this liver function test in normal subjects, the relationship between ALT level and gender, age and body mass index (BMI) was studied in a large population of healthy blood donors. METHODS: This population included 9,420 volunteer blood donors (4,488 men and 4,932 women aged from 18 to 70 years) selected on the basis of negative answers to a detailed medical questionnaire including past medical history, drug and alcohol consumption, on the absence of clinical signs of liver disease, on the negativity of serological testing for hepatitis B and C virus and HIV. RESULTS: In the overall population, the mean serum ALT value was 21.8 I.U./L and the mean BMI was 24.4 kg/m2. There was a positive significant correlation between serum ALT level and BMI (Pearson r = 0.54; p < 0.001) and between ALT and age (Pearson r = 0.25; p < 0.001). A major sex-difference in ALT value was observed, the mean ALT value being higher in men than in women (26.8 +/- 13.6 vs. 17.2 +/- 8.1 I.U./L, p < 0.0001). In both sexes, ALT level was significantly correlated with BMI (Pearson r = 0.45 in men and r = 0.37 in women; p < 0.001). In women a consistent rise in BMI and ALT value with increasing age was observed whereas in men BMI and ALT level only increased with age up to the fifth decade. IN CONCLUSION: There was a significant positive correlation between ALT and BMI regardless the gender in a population of healthy volunteer blood donors. Moreover, at the same age and the same BMI, ALT was significantly lower in women than in men suggesting that the normal range for ALT value should be adjusted for gender. So gender and BMI have to be considered in the interpretation of ALT values.
Subject(s)
Alanine Transaminase/blood , Blood Donors , Body Mass Index , Adolescent , Adult , Age Factors , Aged , Clinical Enzyme Tests , Female , Humans , Liver Diseases/diagnosis , Male , Middle Aged , Reference Values , Sex FactorsABSTRACT
BACKGROUND/AIMS: The place of liver transplantation in hepatitis B viral (HBV)-related diseases remains controversial because of the high rate of reinfection. The aim of this study was to define the determinants of long-term prognosis after transplantation. METHODS: Fifty-eight patients were transplanted during the period February 1984-September 1996. Six patients died during the early (< 3 months) posttransplant period from causes unrelated to HBV infection. All 52 long-term (> 3 months) survivors were evaluated in relation to the mode of presentation, viral replication at time of transplantation, absence of hepatocellular cancer at time of transplantation and use of adequate immunoprophylaxis (IP). Adequate immunoprophylaxis, defined as maintenance of anti-HBs levels over 100 mUI/ml, was introduced in December 1989. Intention-to-treat IP analysis compared patients transplanted before and after this date. The median follow-up was 74 months (range 4 to 131). Forty-seven patients (90%) had a minimal follow-up of 3 years. RESULTS: Five-year actuarial survival rates of 58 patients and of 52 long-term survivors were 72 +/- 6% and 80 +/- 6%, respectively. Univariate analysis showed that delta co-infection (n = 25) significantly improved survival (p < 0.001) [96 +/- 4% vs 63 +/- 10% in HBV patients (n = 27) at 5 years] as did absence of hepatocellular cancer (n = 36) (p = 0.020) [89 +/- 5% vs 61 +/- 12% in 16 non-cancer patients]. IP, however, significantly influenced 5-year survival in the HBV-patient group (n = 17) (p = 0.001) [85 +/- 10% vs 30 +/- 14% in 10 patients without IP). Multivariate analysis selected delta co-infection (p = 0.002) and IP (p = 0.01) as the significant determinants of prognosis independently influencing survival. Uni- and multivariate analyses showed that survival without reinfection was significantly influenced by IP (p = 0.002) [73 +/- 8% (n = 31) versus 33 +/- 12% in 15 non-treated patients). CONCLUSIONS: Delta virus co-infection and immunoprophylaxis are the most important prognostic factors after transplantation for postnecrotic HBsAg-positive cirrhosis. Transplantation can be proposed as a therapeutic tool only if life-long adequate adjuvant therapy can be achieved. Under this condition good results can even be obtained if there is viral replication at the time of transplantation.
Subject(s)
Hepatitis B Surface Antigens/blood , Hepatitis B/surgery , Hepatitis D/surgery , Immunosuppression Therapy/methods , Liver Cirrhosis/surgery , Liver Transplantation/physiology , Actuarial Analysis , Adult , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/surgery , Follow-Up Studies , Hepatitis B/complications , Hepatitis B/therapy , Hepatitis B virus/isolation & purification , Hepatitis B virus/physiology , Hepatitis D/complications , Hepatitis D/therapy , Hepatitis Delta Virus/isolation & purification , Hepatitis Delta Virus/physiology , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunosuppressive Agents/therapeutic use , Immunotherapy , Liver Cirrhosis/etiology , Liver Neoplasms/complications , Liver Neoplasms/surgery , Liver Transplantation/immunology , Liver Transplantation/mortality , Middle Aged , Prognosis , Recurrence , Retrospective Studies , Survival Rate , Virus ReplicationABSTRACT
The case of a young woman with GB virus C/hepatitis G virus (GBV-C/HGV) infection and with a severe exacerbation of chronic hepatitis of unknown etiology during pregnancy is described. In the offspring, severe neonatal hepatitis with subsequent mild chronic liver disease of at least 16-month duration was followed by the development of antibodies to the envelope protein (E2) of GBV-C/HGV, suggesting that the child was recovering from GBV-C/HGV infection. There was an improvement in clinical and biochemical parameters in the mother following delivery and alpha-interferon therapy was associated with a transient biochemical response.
Subject(s)
Flaviviridae/isolation & purification , Hepatitis, Viral, Human/complications , Pregnancy Complications, Infectious/virology , beta-Thalassemia/complications , Adult , Antibodies, Viral/blood , Biopsy, Needle , Female , Flaviviridae/immunology , Hepatitis, Viral, Human/blood , Hepatitis, Viral, Human/immunology , Hepatitis, Viral, Human/pathology , Hepatitis, Viral, Human/therapy , Humans , Infant, Newborn , Infectious Disease Transmission, Vertical , Interferon-alpha/therapeutic use , Liver Function Tests , Polymerase Chain Reaction , Pregnancy , RNA, Viral/bloodABSTRACT
Dietary habits are often considered as a pathogenic factor for fatty liver. The impact of dietary intake and steatosis on drug metabolism remains poorly investigated. Our aim was to assess the effect of dietary intake on in vivo cytochrome P450 (CYP) activities in eleven patients with abnormal liver function tests potentially due to fatty liver and associated with a high-sugar diet. Liver function tests, liver volume, aminopyrine breath test (ABT) and chlorzoxazone (CZ) pharmacokinetics (area under the curve, AUC) which are known to reflect CYP2E1 activity were evaluated before and after 2 months restriction of dietary sugar intake. Features at inclusion were an increased BMI (30.3 (SD 3.2) kg/m2), high hepatic volume (1.96 (SD 0.48) litres), hyperechogenic liver parenchyma, elevated liver enzyme activities (alanine aminotransferase (EC 2.6.1.2) 58.6 (SD 17.4) IU/1 with alanine aminotransferase: aspartate aminotransferase (EC 2.6.1.1) ratio > 1), together with a normal ABT value (0.68 (SD 0.21)% specific activity of administered dose of [14C]aminopyrine in breath after 1 h) and a high CYP2E1 activity (CZ AUC 20.3 (SD 7.1) micrograms/ml per h). A dietary sugar restriction was prescribed. On the basis of repeated interviews by the same dietitian, unaware of any clinical and biochemical data, six patients remained complaint to the diet and exhibited reductions in BMI (P < 0.001), serum alanine aminotransferase (P = 0.008), liver volume (P = 0.002) and CYP2E1 activity (P = 0.007), a significant increase in ABT (P < 0.001) together with the disappearance of liver hyperechogenicity at ultrasound. In contrast, the five non-compliant patients did not show any significant change in any of these variables. In conclusion, CYP2E1 activity is induced in patients with perturbations of liver function tests potentially due to fatty liver. In these patients, effective dietary sugar restriction is associated with a reduction in liver volume, a reduction in CYP2E1 activity and an increased aminopyrine metabolism rate.
Subject(s)
Cytochrome P-450 CYP2E1/metabolism , Dietary Sucrose/administration & dosage , Fatty Liver/enzymology , Feeding Behavior , Liver/enzymology , Adult , Alanine Transaminase/blood , Aminopyridines , Area Under Curve , Aspartate Aminotransferases/blood , Breath Tests , Chlorzoxazone/pharmacokinetics , Fatty Liver/diagnosis , Fatty Liver/metabolism , Female , Humans , Liver/diagnostic imaging , Liver/metabolism , Liver Function Tests , Male , Middle Aged , UltrasonographySubject(s)
Acetaminophen/adverse effects , Analgesics, Non-Narcotic/adverse effects , Chemical and Drug Induced Liver Injury , Liver/pathology , Acetaminophen/administration & dosage , Acetaminophen/toxicity , Aged , Aged, 80 and over , Analgesics, Non-Narcotic/administration & dosage , Analgesics, Non-Narcotic/toxicity , Female , Humans , Injections, IntravenousSubject(s)
Cryoglobulinemia/drug therapy , Cyclosporine/therapeutic use , Glomerulonephritis, Membranoproliferative/drug therapy , Hepatitis C/drug therapy , Immunosuppressive Agents/therapeutic use , Adult , Cryoglobulinemia/complications , Female , Glomerulonephritis, Membranoproliferative/complications , Hepatitis C/complications , Humans , Male , Middle Aged , Treatment FailureABSTRACT
BACKGROUND/AIM: Fatty liver has been associated with an increased risk of primary graft non-function and drug toxicity. However, these effects have been observed mainly in fatty liver with inflammation, a situation characterized by an overall reduction in cytochrome P-450 (CYP)-dependent activities as well as a contrasting increase in CYP2E1 activity. Our aim was to examine the impact of liver-fat accumulation on CYP in two animal models of fatty liver without necroinflammation. METHODS: Ducks were force-fed with a high-glucidic diet and male Wistar rats, after 48 h fasting, were refed a high-glucidic, fat-free diet for 48 h. Total CYP, aminopyrine- (AND), erythromycin-N-demethylase (END) and chlorzoxazone hydroxylase (CZOHase) activities as well as CYP2E1 and CYP3A proteins were quantified on microsomal proteins. RESULTS: Livers from force-fed ducks exhibited significant decreases in total CYP, AND, END and CZOHase activities, inversely correlated with fat-liver content. Refeeding male Wistar rats a high-glucidic, fat-free diet after 48 h fasting, resulting in a 235% increased liver fat content, was associated with a decrease in total CYP (55%), AND (78%), END (55%) and CZOHase (62%) activities as well as in CYP3A (70%) and CYP2E1 (80%) protein content. A significant inverse correlation was observed between CYP and total lipid content. CONCLUSIONS: In these models of steatosis induced by nutritional manipulations, fat liver accumulation was associated with a significant decrease in CYP activities and in CYP protein expression. Furthermore, the decreases in both CYP content and related activities were correlated with the degree of liver fat content.
Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Fatty Liver/metabolism , Lipid Metabolism , Liver/metabolism , Animal Nutritional Physiological Phenomena , Animals , Disease Models, Animal , Fatty Liver/etiology , Fatty Liver/pathology , Liver/pathology , Male , Microsomes, Liver/metabolism , Rats , Rats, WistarABSTRACT
Presystemic metabolism is believed to occur mainly in the liver with some minor intestinal participation. The aim of this study was to investigate the respective part of each of these two organs in the metabolism of the analgesic d-propoxyphene (DP). Pharmacological doses of DP were given in the duodenum (ID), the portal vein (IP), and the femoral vein (IV) of male Wistar rats. A tracer dose of 14C-DP was also administered either in IV, IP, or ID as well as in hepatectomized rats or rats with bile duct diversion. In vitro demethylation occurring in liver and intestinal microsomes was also studied. Absolute DP bioavailability obtained after oral administration was two times higher than that observed after portal administration (48.9% vs. 23.2%, respectively), an result opposite (i.e. a lower bioavailability) of that expected on the basis of the existence of a liver enzyme saturation phenomenon. The 14CO2 cumulative excretion after 14C-DP administration was significantly lower after IV or ID administration than after injection in the portal vein as a bolus or within 20 min. The biliary excretion of the labeled compound varied in the opposite direction, being greater after IV or ID than after IP administration, suggesting that the metabolism of DP in the liver is influenced by an extrahepatic transformation. This most likely occurs in the gut since the production of 14CO2 after IV administration was similar to that after ID administration. This transformation did not prohibit DP detection in the systemic blood but was sufficient to increase the part eliminated with bile and to decrease the part demethylated into NP. Demethylation mainly occurs in the liver since the production of 14CO2 was nearly abolished in hepatectomized rats. Furthermore, microsomes of hepatic but not of intestinal origin were able to demethylate DP. Our data suggest that the transformation of DP occurring in gut after oral administration is responsible for changes in the hepatic metabolism of the drug.
Subject(s)
Analgesics, Opioid/pharmacokinetics , Dextropropoxyphene/pharmacokinetics , Intestinal Mucosa/metabolism , Liver/metabolism , Animals , Area Under Curve , Biotransformation , Dealkylation , Hepatectomy , In Vitro Techniques , Male , Microsomes, Liver/metabolism , Rats , Rats, WistarABSTRACT
Hepatobiliary cystadenoma and cystadenocarcinoma are rare tumors of the liver. The differential diagnosis of cystadenoma includes other cystic neoplasms, nonneoplastic cysts, and even on some occasions parasitic liver involvement. It has been suggested that elevated serum level of the tumor marker CA 19-9 may be of value in distinguishing between cystadenoma with ovarian stroma and hydatid disease. We report the unique case of a male patient with a hepatobiliary cystadenocarcinoma without ovarian stroma of prolonged evolution characterized by a normal CA 19-9 serum level, low cyst fluid CA 19-9, and a very weak CA 19-9 expression on cyst epithelium.